OICHARTS
8 AMThe 8 AM report →

ABUS

Arbutus Biopharma Corporation Common Stock · XNAS · 131 sessions on record
$4.78▲ +0.09 · +1.9%from $4.69 the session before · Sep 30, 2026 close · end of day
Open
$4.68
High
$4.95
Low
$4.68
Day's range
$0.285.9% of the previous close
VWAP
$4.83close −1.1% from it
Volume, shares
16.9M2.63× the 20-session average
Traded, $
$81.6M
Trades
26.8K630 shares per trade
Previous close
$4.69+0.09 to the close
Market cap
$945.7Mat the close of Sep 30
Day range38% of the way up
$4.68$4.95
52-week range53% of the way up
$4.01 Apr 29$5.45 Aug 21

−12% from the high · +19% from the low

Options

No listed options on ABUS

Close $ · S&P 500 rebased to the first close126 sessions to Sep 30 · axis fixed at 4 × ATR-14 around the last close
131 sessions on file · from Mar 25
ABUS close over the last 126 sessions, with S&P 500 rebased to the first close4.124.745.37axis spans 30%S&P 500ABUSApr 1Jul 2Sep 30126 sessions from Apr 1 to Sep 30; the price axis spans 30 percent.

Quarterly results

consolidated · latest filed Aug 12, 2026 · SEC filings

Revenue $1.0M, −91% on a year earlier; profit −$5.1M, −300% in the Jun 2026 quarter, consolidated.

Last 8 quarters, consolidatedUS dollars as filed · year on year against the same quarter a year earlier · market: close on the first session after the filing against the last close before it, S&P 500 over the same session
Quarterly results of ABUS on the consolidated basis with the market's move on the first session after each filing
QuarterRevenue $Revenue YoYProfit $Profit YoYEPS $Market on the day
Jun 2026filed Aug 12$1.0M▼ −91%−$5.1M▼ −300%-0.03▼ −0.2%S&P 500 +0.7% · −0.9 pp
Mar 2026filed Aug 12$179.1M▲ +10,000%$169.7M—0.87▼ −0.2%S&P 500 +0.7% · −0.9 pp
Dec 2025filed Mar 23$1.1M▼ −33%−$3.8M—-0.01—not reached
Sep 2025filed Nov 13$529.0K▼ −60%−$7.7M—-0.04—not reached
Jun 2025filed Aug 12$10.7M▲ +520%$2.5M—0.01▼ −0.2%S&P 500 +0.7% · −0.9 pp
Mar 2025filed Aug 12$1.8M▲ +15%−$24.5M—-0.13▼ −0.2%S&P 500 +0.7% · −0.9 pp
Dec 2024filed Mar 27$1.6M▼ −27%−$12.5M—-0.07—not reached
Sep 2024filed Nov 13$1.3M▼ −71%−$19.7M—-0.10—not reached
By fiscal yearfiscal years as filed in the 10-K · named by the year the fiscal year ends
Financial-year results of ABUS on the consolidated basis, summed from the quarters filed
YearRevenue $Revenue YoYProfit $Profit YoYEPS $
FY25to Dec 2025$14.1M▲ +130%−$33.5M—-0.17
FY24to Dec 2024$6.2M▼ −66%−$69.9M—-0.38
FY23to Dec 2023$18.1M▼ −54%−$72.8M—-0.44
FY22to Dec 2022$39.0M▲ +260%−$69.5M—-0.46
FY21to Dec 2021$11.0M▲ +59%−$76.2M—-0.83

Fundamentals

consolidated · filings to Jun 2026 · close $4.78 on Sep 30

ABUS trades at 6.0 times trailing earnings, 3.7 times book value, revenue +1,100% over twelve months, market cap $945.7M.

Valuation
Market cap
$945.7Mon Sep 30
Price to earnings
6.0consolidated · four quarters to Jun 2026
Trailing EPS
$0.79diluted · consolidated · four quarters to Jun 2026
Price to book
3.7consolidated · balance sheet to Jun 2026
Book value a share
$1.31consolidated · balance sheet to Jun 2026
Debt to equity
0.00borrowings over equity · consolidated · balance sheet to Jun 2026
Return on equity
90%trailing profit over average equity · consolidated
Dividend yield
—
Price to sales
5.2market cap over revenue, four quarters to Jun 2026
Shares outstanding
198Mon Sep 30
Growthsums of the four quarters filed to Jun 2026 · growth against the four quarters before them · consolidated
Revenue, trailing 12 months
$181.7Mfour quarters to Jun 2026
Revenue growth, 12 months
▲ +1,100%against the twelve months before
Revenue 3-year CAGR
▲ +98%trailing twelve months against the twelve months 3 years earlier · consolidated
Profit, trailing 12 months
$153.1Mfour quarters to Jun 2026
Profit growth, 12 months
—
Profit 3-year CAGR
—

Shareholding

quarter to Jun 2026 · SEC Form 13F

13F managers hold 140% of shares, Two Seas Capital LP the largest at 19%, MORGAN STANLEY 18% and Whitefort Capital Management, LP 16%, as filed for the quarter to Jun 2026.

Held by 13F managers
140%of shares outstanding
Shares held
283M−0.47% on Mar 2026 among managers filing both
Managers holding
170158 a quarter earlier
Largest holder
19%Two Seas Capital LP
Largest 10 holderspercent of shares outstanding · change in shares against the previous quarter
Largest 13F holders of ABUS
ManagerSharesOf outstandingValueChange on quarter
Two Seas Capital LP38.2M19%$183.3M+1.08M
MORGAN STANLEY35.4M18%$169.9M−16.4M
Whitefort Capital Management, LP31.6M16%$151.6M+1.73M
BlackRock, Inc.27.5M14%$132.2M+1.6M
STATE STREET CORP15.7M8.0%$75.5M+3.05M
Rubric Capital Management LP15.1M7.6%$72.3M+1.81M
VANGUARD CAPITAL MANAGEMENT LLC14M7.1%$67.3M+644K
BARCLAYS PLC8.42M4.3%$40.4M−216K
GEODE CAPITAL MANAGEMENT, LLC8.24M4.2%$39.5M+692K
GOLDMAN SACHS GROUP INC7.01M3.5%$33.7M+4.81M
Insider tradesSEC Forms 3, 4 and 5 · the latest 2

No open-market insider buying or selling in the last 90 days.

ABUS insider trades
InsiderTradeSharesPriceHeld after
Androski LindsayDirector,Officergranted · Feb 2, 202628,000$0.0028,000
Nguyen TuanOfficergranted · Feb 2, 202673,500$0.0073,500

Corporate actions

exchange records

No corporate action on record for ABUS yet.

Price history

131 sessions on record · to Sep 30 · end of day

ABUS is −6.1% over 20 sessions against the S&P 500's +0.1%, 12% below its 52-week high, realised volatility 20% annualised.

Returns against S&P 500longest window first · S&P 500 over the same sessions
Returns of the stock and S&P 500 over six windows, longest first
WindowFrom $ABUS %S&P 500 %Difference pp
120 sessionssince Apr 9$4.30▲ +11%▲ +12%−1.0
60 sessionssince Jul 7$5.18▼ −7.7%▲ +2.0%−9.7
20 sessionssince Sep 1$5.09▼ −6.1%▲ +0.11%−6.2
5 sessionssince Sep 23$4.85▼ −1.4%▼ −0.67%−0.77
1 sessionsince Sep 29$4.69▲ +1.9%▼ −0.21%+2.1
Averages of the closeclose against each average
5-session average
$4.81close −0.62% from it
20-session average
$5.01close −4.6% from it
50-session average
$4.83close −1.0% from it
Range and volumetrue range over 14 sessions · high to low over 20 · volume against the 20-session average
Average true range, 14
$0.112.3% of the close
Average day's range, 20
$0.102.1% of the close
Volume against 20 sessions
2.63×16.9M vs 7.13M average
Volatility and co-movement with S&P 500annualised from daily returns
Realised volatility, 20
20%≈ ±1.3% a session · moved more than that on 4 of 20
Realised volatility, 60
38%≈ ±2.4% a session · moved more than that on 17 of 60
Beta to S&P 500, 60
0.58moved with S&P 500 on 28 of 60 sessions
Up and down sessionscloses above and below the previous close
Last 20 sessions
10 up · 9 downof 19
Last 60 sessions
28 up · 29 downof 57
Best session, 250
▲ +9.2%Aug 21
Worst session, 250
▼ −6.6%Jul 10

Short-sale volume

25 sessions · to Sep 30, 2026

Short sales were 72% of reported volume on Sep 30, 2026, against 55% over the last 25 sessions.

Last 10 sessionsshare of the day's reported volume
ABUS daily short-sale volume
SessionShort volumeReported volumeShort share
Sep 30, 20263.67M5.13M71.7%
Sep 29, 20262.82M4.4M64.0%
Sep 28, 20262.94M4.58M64.2%
Sep 25, 20263.12M4.11M75.8%
Sep 24, 20261.64M2.11M77.7%
Sep 23, 20262.01M3.06M65.9%
Sep 22, 2026368K2.66M13.8%
Sep 21, 2026528K863K61.2%
Sep 18, 20261.64M1.99M82.5%
Sep 17, 2026454K1.08M42.0%

Filings

SEC EDGAR · newest first
ABUS SEC filings
FiledFormReport date
Sep 23, 20264Sep 18, 2026
Sep 23, 20264Sep 18, 2026
Sep 23, 20264Sep 18, 2026
Sep 23, 20264Sep 18, 2026
Sep 4, 2026SCHEDULE 13G—
Aug 24, 2026SC TO-I—
Aug 21, 2026SC TO-C—
Aug 21, 20268-KAug 21, 2026
Aug 12, 202610-QJun 30, 2026
Aug 12, 20268-KAug 12, 2026
Aug 12, 2026SCHEDULE 13G/A—
Jul 16, 20268-KJul 15, 2026
Jun 10, 20264Jun 8, 2026
Jun 10, 20264Jun 8, 2026
Jun 5, 2026S-8—
May 27, 20268-KMay 26, 2026
May 15, 2026SCHEDULE 13G/A—
May 13, 202610-QMar 31, 2026
May 13, 20268-KMay 13, 2026
Apr 28, 2026SCHEDULE 13D/A—
Apr 15, 20268-KApr 14, 2026
Apr 14, 2026DEFA14A—
Apr 14, 2026DEF 14AMay 26, 2026
Apr 13, 2026SCHEDULE 13D/A—
Mar 23, 202610-KDec 31, 2025

About Arbutus Biopharma Corporation Common Stock

SEC and exchange records
Company
Arbutus Biopharma Corporation Common Stock
Exchange
XNAS
SEC CIK
1447028
Sessions on record
131
Price source
End of day · delayed
Computed
1 Oct, 09:28 pm IST

OI Charts is not a registered investment adviser or broker-dealer. Prices, filings and open interest are public data and arithmetic on it, not a basis for any investment decision.